{"organizations": [], "uuid": "aee80ed145dc0e7bd25c982d275ea7c105572444", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/03/12/the-associated-press-iovance-biotherapeutics-posts-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Iovance Biotherapeutics posts 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T23:23:00.000+02:00", "replies_count": 0, "uuid": "aee80ed145dc0e7bd25c982d275ea7c105572444"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/03/12/the-associated-press-iovance-biotherapeutics-posts-4q-loss.html", "ord_in_thread": 0, "title": "Iovance Biotherapeutics posts 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "calif.", "sentiment": "none"}, {"name": "san carlos", "sentiment": "none"}, {"name": "san carlos", "sentiment": "none"}], "organizations": [{"name": "iova", "sentiment": "negative"}, {"name": "iovance biotherapeutics", "sentiment": "negative"}, {"name": "iovance biotherapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN CARLOS, Calif. (AP) _ Iovance Biotherapeutics Inc. (IOVA) on Monday reported a loss of $25.9 million in its fourth quarter.\nOn a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. Losses, adjusted for stock option expense, came to 32 cents per share.\nThe results met Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for a loss of 32 cents per share.\nFor the year, the company reported that its loss narrowed to $92.1 million, or $1.41 per share.\nIovance Biotherapeutics shares have more than doubled since the beginning of the year. In the final minutes of trading on Monday, shares hit $19.15, more than doubling in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on IOVA at https://www.zacks.com/ap/IOVA", "external_links": [], "published": "2018-03-12T23:23:00.000+02:00", "crawled": "2018-03-13T03:38:29.041+02:00", "highlightTitle": ""}